1 |
Karuppagounder SS, Wang H, Kelly T, Rush R, Nguyen R, Bisen S, Yamashita Y, Sloan N, Dang B, Sigmon A, Lee HW, Marino Lee S, Watkins L, Kim E, Brahmachari S, Kumar M, Werner MH, Dawson TM, Dawson VL. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med 2023;15:eabp9352. [PMID: 36652533 DOI: 10.1126/scitranslmed.abp9352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Marín T, Valls C, Jerez C, Huerta T, Elgueta D, Vidal RL, Alvarez AR, Cancino GI. The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model. IBRO Neurosci Rep 2022;13:378-87. [PMID: 36590096 DOI: 10.1016/j.ibneur.2022.10.006] [Reference Citation Analysis]
|
3 |
Khairnar RC, Parihar N, Prabhavalkar KS, Bhatt LK. Emerging targets signaling for inflammation in Parkinson's disease drug discovery. Metab Brain Dis 2022. [PMID: 35536461 DOI: 10.1007/s11011-022-00999-2] [Reference Citation Analysis]
|
4 |
Liu W, Wu L, Li D, Huang Y, Liu M, Liu W, Tian C, Liu X, Jiang X, Hu X, Gao X, Xu Z, Lu H, Zhao Q. Discovery of Novel Tacrine Derivatives as Potent Antiproliferative Agents with CDKs Inhibitory Property. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
5 |
Giesert F. c-Abl phosphorylation primes PARIS for neurodegeneration. Brain 2021;144:3555-7. [PMID: 34788407 DOI: 10.1093/brain/awab412] [Reference Citation Analysis]
|
6 |
Espay AJ. Movement disorders research in 2021: cracking the paradigm. Lancet Neurol 2022;21:10-1. [PMID: 34942122 DOI: 10.1016/S1474-4422(21)00413-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|